Feasibility of Asthma Review and Management in New Zealand Community Pharmacy - a Single Cohort, Open Label, Non-Randomised Pilot Study

Medical Research Institute of New Zealand0 个研究点目标入组 25 人开始时间: 2022年8月31日最近更新: 2022年9月12日

试验速览

暂无简介。

•Participants are eligible to be included in the study only if all the following criteria apply:
•1.Willing and able to provide written informed consent
•2.Adults aged 18 to 65 years.
•3.Physician diagnosis of asthma.
•4.Have a prescription for Budesonide/formoterol 200µg/6µg (Symbicort® Turbuhaler) taken as required, per AIR algorithm step 1.
•5.Access to a mobile phone and/or device with internet connectivity to complete remote assessments.
•6.Willingness and ability to return for a follow up visit at week 12.
•7.Willing to attend the study pharmacy for their asthma reviews throughout the length of the study.
•8.Willing and able to comply with the study instructions.

•Participants are excluded from the study if any of the following criteria apply:
•1.Other chronic respiratory disease, such as COPD, Interstitial lung disease, etc.
•2.Any acute or chronic medical condition that the investigator considers may impact the validity and reliability of the study results.
•3.Current use of Budesonide/formoterol 200µg/6µg (Symbicort® Turbuhaler) as maintenance therapy per AIR algorithm step 2 or 3
•4.Current use of any other inhaled medication for asthma.
•5.Current use of theophylline, leukotriene receptor antagonist, sodium cromoglycate, nedocromil sodium or monoclonal antibody therapy for asthma.
•6.Current use or use within the preceding 6 weeks of oral steroids.
•7.Cognitive impairment preventing the participant from understanding the trial instructions or requires assistance in management of medications, complete questionnaires, or provide informed consent.
•8.Active involvement in any clinical trial, or recent involvement in an interventional trial in the past 12 weeks.

发起方